Looks like the FDA needs a hand making a decision.
ODAC to the rescue. Now that would be a good nights entertainment.
All of the REACH trials 1 , 2 & 3 were complete rubbish and even then they only proved how dangerous the drug is. As for efficacy the way they were put together in a open label manner with inclusion exclusion criteria renders that data meaningless.
@stanjupiter may like to add a citizen partition for discussion .
Looks like the FDA needs a hand making a decision. ODAC to the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |